Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Share-based Compensation (2022 - 2025)

CervoMed's Share-based Compensation history spans 9 years, with the latest figure at $291717.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 7.56% year-over-year to $291717.0; the TTM value through Sep 2025 reached $1.5 million, up 20.65%, while the annual FY2024 figure was $1.4 million, 244.85% up from the prior year.
  • Share-based Compensation for Q3 2025 was $291717.0 at CervoMed, down from $497015.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $578581.0 in Q2 2024 and bottomed at -$428745.0 in Q3 2022.
  • The 4-year median for Share-based Compensation is $271215.0 (2024), against an average of $219805.9.
  • The largest annual shift saw Share-based Compensation tumbled 77.62% in 2023 before it surged 829.42% in 2024.
  • A 4-year view of Share-based Compensation shows it stood at $206319.0 in 2022, then fell by 20.04% to $164972.0 in 2023, then soared by 104.71% to $337711.0 in 2024, then decreased by 13.62% to $291717.0 in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Share-based Compensation are $291717.0 (Q3 2025), $497015.0 (Q2 2025), and $361167.0 (Q1 2025).